Podcast episode: how a failed venous ulcer treatment led to the SkinMedica TNS serum
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedIn this episode description, SkinMedica co-founder Dr. Mitchel Goldman recounts how a failed venous ulcer treatment became the TNS growth factor serum, which he calls a longevity product from decades before the term existed. [1]
The description says a failed treatment for venous ulcers became the TNS serum, which Goldman calls a longevity product from decades before the term existed. [1]
A passing comment from Dr. Richard Fitzpatrick about the skin around a wound is said to have led to the first growth factor serum. [1]
The description lists topics including growth factor and exosome products, pre- and post-procedure skincare, and Goldman's caution about systemic anti-aging therapies. [1]
Goldman on TNS origins and company finances
The description says the episode features Dr. Mitchel Goldman, co-founder of SkinMedica, in conversation with Dr. Ted Lain. Goldman describes how a failed treatment for venous ulcers became TNS, which he calls one of the most influential products in professional skincare and a longevity product decades before the term existed. A passing comment from Dr. Richard Fitzpatrick about the skin around a wound is said to have led to the first growth factor serum. Goldman also discusses the hard financial realities of building a skincare company and why physician-dispensed brands that invest in research stand apart. [1]
Growth factors, exosomes and procedure skincare
The description lists further topics: why the full mixture of growth factors, secretomes and exosomes is said to outperform any single ingredient; how Goldman rotates growth factor products and lets patients' results guide the choice; and pre- and post-procedure skincare, including a shift toward priming fibroblasts with topical rapamycin. It also names whether skin longevity needs multi-targeted or single-pathway products. These are described as topics covered, not as results of a reported study. [1]
Systemic anti-aging caution and other episode topics
The description also mentions Goldman's personal cautionary tale about systemic anti-aging therapies and why he favors topicals. It says a topical sodium bicarbonate made for athletes is now being studied in oncology, and that the episode argues aesthetic dermatology deserves a bigger place in residency training. The description ends with a disclaimer that the episode is not intended to provide diagnosis, treatment or medical advice and is for educational purposes only. [1]
Context & limits
This is based only on the supplied video description; the video and transcript were not reviewed. The description lists conversation topics and creator statements, not study designs, samples or measured outcomes, so no efficacy or safety conclusions can be drawn.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
failed treatment for venous ulcers became
led to the first growth factor serum
A cautionary tale on systemic anti-aging
About this video
Creator description · original textText language: English
The Science of Skin Podcast · 34 min · Source published: 2026-10-13
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.